论文部分内容阅读
幽门螺杆菌(Hp)目前的研究包括:①除菌治疗以抑制诱发胃癌已形成全球性推进趋势;②应用甲硝唑作二次性除菌已纳入日本医保;③日本的除菌疗法首选是ITP新治疗方案。对GERD及Barrett食管的世界性标准定义进行探讨,对RomeⅢ功能性胃肠病(FD)的定义与诊断标准进行修定。NSAIDs是后Hp时代最重要的胃黏膜损害因子。ESD于2006年4月纳入医保,而其顺利推行尚须构建教育体系。
Helicobacter pylori (Hp) current research includes: ① sterilization treatment to inhibit the development of gastric cancer has formed a global trend; ② application of metronidazole for secondary sterilization has been included in the Japanese health insurance; ③ Japan’s preferred sterilization is ITP new treatment options. The definition of GERD and Barrett’s esophagus worldwide standard definition of discussion, Rome Ⅲ functional gastrointestinal disease (FD) definition and diagnostic criteria were revised. NSAIDs are the most important gastric mucosal damage factors in the post-Hp era. ESD was included in Medicare in April 2006, and its smooth implementation still requires building an education system.